Progress in the clinical use of radiotherapy for bone metastasis in breast cancer

doi:10.3969/j.issn.1007-3969.2016.04.010

Abstract

Abstract: Bone remains the predominant site of metastasis in advanced breast cancer. Bone metastases dramatically decrease the quality of life. Moreover, pathologic fractures and other skeletal-related events (SREs) caused by bone metastases could result in higher mortality risk in patients with breast cancer. Palliative radiotherapy is a crucial element in bone metastases treatment. The present review discusses the emerging evidence in bone metastases of breast cancer, focusing on optimized radiotherapy strategies and multidisciplinary management.

Key words: Breast neoplasms, Bone metastasis, Skeletal-related events, Radiotherapy, Multidisciplinary management

HU Qunchao, YU Xiaoli, GUO Xiaomao. Progress in the clinical use of radiotherapy for bone metastasis in breast cancer[J]. China Oncology, 2016, 26(4): 346-350.

[1]	HU Xiaoyu, CAI Yuwen, YE Fugui, SHAO Zhimin, HU Weigang, YU Keda. Impact of BRCA1/2 germline mutation on the incidence of second primary cancer following postoperative radiotherapy in patients with triple-negative breast cancer [J]. China Oncology, 2024, 34(2): 185-190.
[2]	LIU Zhiyu, XU Dong, CHEN Xihao, LI Jipeng. Influencing factors and establishment of a prediction model for the tumor regression after neoadjuvant chemoradiotherapy in locally advanced rectal cancer [J]. China Oncology, 2024, 34(2): 191-200.
[3]	CHEN Hongyu, SU Pengyu, LUO Wenzi, PANG Dequan, WANG Feiran. A study of relationship between cardiac exposure dose-volume and cardiovascular autonomic dysfunction in radiotherapy [J]. China Oncology, 2024, 34(11): 1036-1044.
[4]	OUYANG Fei, WANG Yang, CHEN Yu, PEI Guoqing, WANG Ling, ZHANG Yang, SHI Lei. Construction of the prediction model of breast cancer bone metastasis based on machine learning [J]. China Oncology, 2024, 34(10): 903-914.
[5]	CUI Jianchun, LU Wei, LI Qianyong. Clinical application value of surface-guided automatic positioning in pelvic tumor radiotherapy [J]. China Oncology, 2024, 34(10): 966-971.
[6]	CHEN Man, ZENG Feiyan, LI Qingqing, LI Hongdan, LIN Yansong, FENG Ping. A meta-analysis of the efficacy of ⁹⁹Tc-MDP alone and in combination with ⁸⁹SrCl₂ in the treatment of bone metastases [J]. China Oncology, 2023, 33(8): 751-767.
[7]	WANG Yan, SU Yue, HU Tu, LIU Qiying, YAO Weiqiang, CHEN Yong, YAN Wangjun, ZHANG Zhen. Retrospective analysis of short-term efficacy and safety of preoperative radiotherapy for 33 cases of locally high-risk soft tissue sarcoma [J]. China Oncology, 2023, 33(7): 693-700.
[8]	BI Zhao, WANG Yongsheng. New concept of de-escalation management strategy in breast cancer patients with 1-2 positive sentinel lymph nodes [J]. China Oncology, 2023, 33(6): 560-565.
[9]	DONG Xiaohuan, LIU Jun, LI Hongxuan, CHENG Yan, LI Yue, YU Wen, CAI Xuwei, FU Xiaolong. Preliminary study on involving field irradiation radiotherapy in neoadjuvant chemoradiotherapy for esophageal cancer [J]. China Oncology, 2023, 33(3): 267-273.
[10]	TANG Tianci, ZHAI Zhoushijia, LI Shengwei, WANG Xiaoshen, NI Xiaochen. Application of generalized equivalent uniform dose optimization in the treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy [J]. China Oncology, 2023, 33(3): 274-281.
[11]	WANG Yu, BI Nan. Advancements in the research of immunomodulatory effects of radiation therapy: from basic to clinical [J]. China Oncology, 2023, 33(12): 1083-1091.
[12]	ZHUANG Han, LING Chifang, WANG Jiazhou, HAN Xu, JIANG Rui, HU Weigang. Radiation therapy in locally advanced pancreatic cancer with 75 Gy simultaneous integrated boost: a dosimetric feasibility study [J]. China Oncology, 2023, 33(1): 54-60.
[13]	CAI Gang, WANG Shubei, CHEN Jiayi. The current data and challenge of radiotherapy in the case management of gastric cancer [J]. China Oncology, 2022, 32(7): 581-587.
[14]	HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu. Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(7): 624-634.
[15]	YU Silai, NI Jianjiao, ZHU Zhengfei. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects [J]. China Oncology, 2022, 32(6): 487-498.

Progress in the clinical use of radiotherapy for bone metastasis in breast cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments